Yaghi Shadi, Kamel Hooman, Elkind Mitchell S V
a Department of Neurology, Division of Stroke and Cerebrovascular Diseases , The Warren Alpert Medical School of Brown University , Providence , RI , USA.
b Departments of Neurology and Feil Family Brain and Mind Research Institute , Weill Cornell Medical College , New York , NY , USA.
Expert Rev Cardiovasc Ther. 2017 Aug;15(8):591-599. doi: 10.1080/14779072.2017.1355238. Epub 2017 Jul 27.
Cryptogenic stroke accounts for approximately 30% of all ischemic strokes. Recently, atrial cardiopathy diagnosed by the presence of one of its serum, imaging, or electrocardiogram biomarkers has been shown to be associated with ischemic stroke, particularly of embolic subtypes. Areas covered: This paper aims to summarize data on occult atrial fibrillation and stroke, provide an overview on mechanisms, such as inflammation and fibrosis, of stroke in atrial cardiopathy, critically review data on biomarkers of atrial cardiopathy and their association with stroke, and suggest therapeutic implications, including directions for future research. Expert commentary: Atrial cardiopathy may constitute one of the mechanisms in cryptogenic stroke, and patients with evidence of atrial cardiopathy constitute a group of patients in whom clinical trials are warranted to test anticoagulation versus antiplatelet therapy to reduce stroke recurrence risk. In addition, more studies are needed to determine the degree of overlap between these atrial cardiopathy biomarkers and which one is more useful in predicting the risk of stroke and response to anticoagulation therapy.
隐源性卒中约占所有缺血性卒中的30%。最近,通过其血清、影像学或心电图生物标志物之一诊断出的心房病变已被证明与缺血性卒中有关,尤其是栓塞亚型。涵盖领域:本文旨在总结隐匿性房颤与卒中的数据,概述心房病变中卒中的机制,如炎症和纤维化,批判性地回顾心房病变生物标志物及其与卒中关联的数据,并提出治疗意义,包括未来研究方向。专家评论:心房病变可能是隐源性卒中的机制之一,有证据表明存在心房病变的患者构成了一组有必要进行临床试验以测试抗凝与抗血小板治疗以降低卒中复发风险的患者群体。此外,需要更多研究来确定这些心房病变生物标志物之间的重叠程度,以及哪一种在预测卒中风险和对抗凝治疗的反应方面更有用。